Articles > Popular publications > PR Newswire press releases > July-September 1997 > Tuesday, July 8

Article: DuPont Merck and Elan Establish Parkinson's Disease Alliance

Article from:
PR Newswire
Article date:
July 8, 1997
Copyright

WILMINGTON, Del., and DUBLIN, Ireland, July 8 /PRNewswire/ -- The DuPont Merck Pharmaceutical Company ("DuPont Merck") and Elan Corporation, plc (NYSE: ELN) ("Elan") announced today their alliance to co-promote in the United States their respective leading Parkinson's disease products, Sinemet(R) CR (carbidopa-levodopa sustained release) and Permax(R) (pergolide mesylate). The alliance will be implemented by the sales force of Elan's wholly owned subsidiary, Athena Neurosciences, Inc. ("Athena") and DuPont Merck.

"The purpose of this alliance is to consolidate and clarify therapeutic messages given to physicians," said Nick Teti, president worldwide ...

Read all of this article with a FREE trial

Related newspaper, magazine, and journal articles:

Article: IMPAX Comments on Merck's Lawsuit Related to Generic Version of ...
Business Wire;  February 24, 2003 ;     700+ words ... ... version of Sinemet(R) CR tablets. Sinemet CR is used to treat patients with Parkinsonism ... Company (NYSE: BMY). U.S. sales of Sinemet CR and the currently marketed generic equivalent ... market a generic version of Merck's Sinemet CR in December 2002. IMPAX's submission ...

Article: FDA approves generic version of Sinemet CR.
Drug Week;  June 18, 2004 ;     524 words ... ... Release Tablets, its generic version of Sinemet CR tablets. Bristol-Myers Squibb (BMY) markets Merck & Co.'s (MRK) Sinemet CR exclusively in the U.S. for the treatment ... NDCHealth, U.S. prescription sales of Sinemet CR and the one currently marketed generic ...

Article: IMPAX gets FDA approval for generic Sinemet ...
Pharma Marketletter;  May 24, 2004 ;     610 words ... ... release tablets, its generic version of Sinemet CR tablets. Bristol-Myers Squibb markets Merck & Co's Sinemet CR exclusively in the USA for the treatment ... NDCHealth, US prescription sales of Sinemet CR and the one currently-marketed generic ...

Article: Sun Pharm gets USFDA nod for generic Sinemet CR.
PTI - The Press Trust of India Ltd.;  August 25, 2007 ;     514 words ...Sun Pharm gets USFDA nod for generic Sinemet CR New Delhi, Aug 25 (PTI) Drug maker ... equivalent of Bristol Myers Squibs' Sinemet CR, which has sales of 66 million dollars ... with levodopa are bio-equivalent to Sinemet CR and would be available in two strengths ...

Article: IMPAX Announces Merck's Withdrawal of Lawsuit Related to Generic ...
Business Wire;  April 9, 2003 ;     700+ words ... ... court in Delaware in February 2003. Sinemet CR is used to treat patients with Parkinsonism ... Company (NYSE:BMY). U.S. sales of Sinemet CR and the currently marketed generic equivalent ... market a generic version of Merck's Sinemet CR in December 2002. IMPAX has 19 applications ...

Article: IMPAX Receives Final FDA Approval for Generic Version of ...
Business Wire;  May 17, 2004 ;     700+ words ... ... BMY) markets Merck & Co.'s (NYSE:MRK) Sinemet CR exclusively in the U.S. for the treatment of Parkinsonism ... According to NDCHealth, U.S. prescription sales of Sinemet CR and the one currently marketed generic equivalent were ...

Article: DuPont Merck and Signal Pharmaceuticals Form ...
PR Newswire;  January 13, 1998 ;     700+ words ... ... DIEGO, Jan. 13 /PRNewswire/ -- DuPont Merck and Signal Pharmaceuticals, Inc. today ... HIV. Under terms of the agreement, DuPont Merck will provide research funding to Signal ... initial three years of the collaboration. DuPont Merck will make upfront and milestone payments ...

Article: CYTOGEN AND DUPONT MERCK FINALIZE AGREEMENT
PR Newswire;  December 20, 1994 ;     700+ words ... ... collaborative agreement with the Radiopharmaceuticals Division of The DuPont Merck Pharmaceutical Company (DuPont Merck). Under the terms of the agreement, DuPont Merck will have the primary responsibility for manufacturing and marketing ...

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!

Find articles, research, and archives